AXSM (Axsome Therapeutics) Total Payout Ratio: 0.29 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AXSM Axsome Therapeutics Inc AXSM
52 GF Score
Price $234.82
GF Value $225.01
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Axsome Therapeutics Total Payout Ratio?

Axsome Therapeutics AXSM -1.14% 52 Total Payout Ratio is 0.29 as of Jul. 16, 2026. GuruFocus rates AXSM with a GF Score™ of 52/100 and a GF Value™ of $225.01 (Fairly Valued). The stock has 4 warning signs investors should review.

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Axsome Therapeutics's current Total Payout Ratio is 0.29.

Axsome Therapeutics Total Payout Ratio Related Terms

Axsome Therapeutics Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Axsome Therapeutics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axsome Therapeutics Total Payout Ratio Chart

Axsome Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 1.30 1.08 0.14 0.37

Axsome Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.68 0.21 0.20 0.10

AXSM vs MDGL, IONS, BMRN: Total Payout Ratio Comparison

For the Biotechnology subindustry, Axsome Therapeutics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Axsome Therapeutics Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's Total Payout Ratio falls into.


AXSM
52GF Score
Axsome Therapeutics Inc AXSM
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Axsome Therapeutics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Axsome Therapeutics's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 67.904 + 0) / -183.174
=0.37

Axsome Therapeutics's Total Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 6.343 + 0) / -64.542
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Ratio →
What does a Total Payout Ratio of 0.29 mean?
Axsome Therapeutics (AXSM) has a Total Payout Ratio of 0.29 as of Jul. 16, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Axsome Therapeutics and its competitors.
Is Axsome Therapeutics' Total Payout Ratio too high?
Axsome Therapeutics' current Total Payout Ratio is 0.29. Overall, Axsome Therapeutics has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' Total Payout Ratio compare to MDGL and IONS?
Axsome Therapeutics' Total Payout Ratio of 0.29 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Biotechnology company?
A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Axsome Therapeutics and its competitors. Axsome Therapeutics's current Total Payout Ratio is 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (AXSM) is currently considered Fairly Valued. The stock's GF Value™ is $225.01, compared to a current price of $234.82 — trading 4.4% above its estimated fair value. The current Total Payout Ratio is 0.29. Axsome Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Axsome Therapeutics (AXSM), the current Total Payout Ratio is 0.29 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axsome Therapeutics (AXSM) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of $234.82 is trading 4.4% above its estimated GF Value™ of $225.01. GuruFocus considers Axsome Therapeutics to be Fairly Valued.

Key valuation signals for AXSM:

  • Total Payout Ratio: 0.29
  • GF Value™: $225.01 vs. price of $234.82 (4.4% above fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Axsome Therapeutics Business Description

Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score

Get the complete analysis for AXSM

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$234.82
Price
$225.01
GF Value